» Articles » PMID: 17488496

Understanding the Effects of a Decentralized Budget on Physicians' Compliance with Guidelines for Statin Prescription--a Multilevel Methodological Approach

Overview
Publisher Biomed Central
Specialty Health Services
Date 2007 May 10
PMID 17488496
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Official guidelines that promote evidence-based and cost-effective prescribing are of main relevance for obvious reasons. However, to what extent these guidelines are followed and their conditioning factors at different levels of the health care system are still insufficiently known. In January 2004, a decentralized drug budget was implemented in the county of Scania, Sweden. Focusing on lipid-lowering drugs (i.e., statins), we evaluated the effect of this intervention across a 25-month period. We expected that increased local economic responsibility would promote prescribing of recommended statins.

Methods: We performed two separate multilevel regression analyses; on 110,827 individual prescriptions issued at 136 publicly-administered health care centres (HCCs) nested within 14 administrative areas (HCAs), and on 72,012 individual prescriptions issued by 115 privately-administered HCCs. Temporal trends in the prevalence of prescription of recommended statins were investigated by random slope analysis. Differences (i.e., variance) between HCCs and between HCAs were expressed by median odds ratio (MOR).

Results: After the implementation of the decentralized drug budget, adherence to guidelines increased continuously. At the end of the observation period, however, practice variation remained high. Prescription of recommended statins presented a high degree of clustering within both publicly (i.e., MORHCC = 2.18 and MORHCA = 1.31 respectively) and privately administered facilities (MORHCC = 3.47).

Conclusion: A decentralized drug budget seems to promote adherence to guidelines for statin prescription. However, the high practice differences at the end of the observation period may reflect inefficient therapeutic traditions, and indicates that rational statin prescription could be further improved.

Citing Articles

The median hazard ratio: a useful measure of variance and general contextual effects in multilevel survival analysis.

Austin P, Wagner P, Merlo J Stat Med. 2016; 36(6):928-938.

PMID: 27885709 PMC: 5299617. DOI: 10.1002/sim.7188.


Pharmaceutical policies: effects of financial incentives for prescribers.

Rashidian A, Omidvari A, Vali Y, Sturm H, Oxman A Cochrane Database Syst Rev. 2015; (8):CD006731.

PMID: 26239041 PMC: 7390265. DOI: 10.1002/14651858.CD006731.pub2.


Exploring sources of variability in adherence to guidelines across hospitals in low-income settings: a multi-level analysis of a cross-sectional survey of 22 hospitals.

Gathara D, English M, Boele van Hensbroek M, Todd J, Allen E Implement Sci. 2015; 10:60.

PMID: 25928803 PMC: 4416316. DOI: 10.1186/s13012-015-0245-x.


Should hospital pharmacy drug budgets be the responsibility of each individual department in an institution, or should such budgets be controlled centrally by the pharmacy department?.

Can J Hosp Pharm. 2012; 63(4):330-2.

PMID: 22478998 PMC: 2932500. DOI: 10.4212/cjhp.v63i4.939.


Practice variation in a longitudinal perspective: a multilevel analysis of the prescription of simvastatin in general practices between 2003 and 2009.

Ohlsson H, Vervloet M, van Dijk L Eur J Clin Pharmacol. 2011; 67(12):1205-11.

PMID: 21698375 DOI: 10.1007/s00228-011-1082-8.


References
1.
Davis P, Gribben B, Lay-Yee R, Scott A . How much variation in clinical activity is there between general practitioners? A multi-level analysis of decision-making in primary care. J Health Serv Res Policy. 2002; 7(4):202-8. DOI: 10.1258/135581902320432723. View

2.
Gonzalez Lopez-Valcarcel B, Ortun Rubio V, Martin Oliva J, Cabeza Mora A, Lopez Cabanas A, Diaz Berenguer J . [Evaluation of the proper use of medicines in primary care. How can this be improved?]. Aten Primaria. 2002; 30(7):467-71. PMC: 7669146. DOI: 10.1016/s0212-6567(02)79074-4. View

3.
. The statin wars: why AstraZeneca must retreat. Lancet. 2003; 362(9393):1341. View

4.
Grimshaw J, Thomas R, MacLennan G, Fraser C, Ramsay C, Vale L . Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004; 8(6):iii-iv, 1-72. DOI: 10.3310/hta8060. View

5.
WENNBERG J, BARNES B, Zubkoff M . Professional uncertainty and the problem of supplier-induced demand. Soc Sci Med. 1982; 16(7):811-24. DOI: 10.1016/0277-9536(82)90234-9. View